Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis

Sponsor
Sun Yat-sen University
Study ID
NCT04588818
Phase
PHASE2
Status
Unknown

Conditions

  • Uveitis

Eligibility Criteria

Sex
ALL
Age
2 Years - 16 Years
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab plus Methotrexate — DRUG
    Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose. Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) .

Study Details

The aim of this study is to determine the efficacy and safety of ADA plus MTX for the treatment in non-infectious pediatric panuveitis.

Key Dates

Start date
Feb 1, 2020
Status verified
Dec 2021
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adalimumab plus Methotrexate

Primary Outcome Measure

the time to reach the remission [ Time Frame: 12 months ]

Central Contacts

Related Studies